															CIC)N	IS I	FO	RN
SUSPE	CT ADVERSE	REAC	TION REPO	RT															
								П	\perp	Т	П	$\overline{}$	Т	Т	\top	Т	Т	Τ	Т
															丄	L			\perp
			I. REA	CTION	INFOR	MATION	1												
1. PATIENT INITIALS (first, last)	, last)								ET Year	8-1	Α	PPF	CK ALL ROPRIA	ATE					
PRIVACY	Female								ADVERSE REACTION										
7 + 13 DESCRIBE REACTION(S) (including relevant tests/lab data) Event Verbatim [LOWER LEVEL TERM] (Related symptoms if any separated by commas) Indication: Ankylosing Spondylitis [Off label use in unapproved indication]										PATIENT DIED INVOLVED OR PROLONGED INPATIENT									
Case Description information team	nsumer or	ner or other non HCP from medical							HOSPITALISATION INVOLVED PERSISTENT										
A female patient received parecoxib sodium (VALDUREIM), at 40mg/2ml for ankylosing spondylitis. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: OFF LABEL USE (non-serious), described as "Indication: Ankylosing Spondylitis".											OR SIGNIFICANT DISABILITY OR INCAPACITY								
Spondyillis .					(Conti	nued on Ad	dition	al In	format	ion F	Page)]	IFE HRE	EATENI	ING			
			II. SUSPEC	T DRL	JG(S) IN	FORMA	TIO	N											
14. SUSPECT DRUG(S) (include generic name) #1) Valdureim (PARECOXIB SODIUM) Powder and solvent for solution for injection										20. DID REACTION ABATE AFTER STOPPING DRUG?									
						ROUTE(S) OF ADMINISTRATION) Unknown							YES NO NA						
17. INDICATION(s) FOR USE #1) Ankylosing Spondylitis (Ankylosing spondylitis)										21. DID REACTION REAPPEAR AFTER REINTRODUCTION?									
` ' '						THERAPY DURATION) Unknown							YES NO NA						
22 CONCOMITANT DRI	UG(S) AND DATES OF AL		CONCOMITION (exclude those us) AND H	IST	OR'	Υ							_			
22. 001100111111111111111111111111111111	00(0) AND DITES 3	JVIII VIO 1	Old (excludesss 22	360 10 11 301 .	eaction,														
23. OTHER RELEVANT From/To Dates Unknown	HISTORY. (e.g. diagnostic		oregnancy with last more of History / Notes	onth of perio	od, etc.) Description														
3																			
			IV. MANUF	FACTU	RER IN	ORMAT	ΓΙΟΝ	1		_									
24a. NAME AND ADDRE Pfizer S.A.	26. REM	IARKS										_							
Laura Arce Mora Avenida Escazú, 1 San Jose, COS1																			
San Juse, Coo.	IA RICA																		
	24b. MFR (CONTROL NO	 D.		25b. NA	ME AND ADDE	RESS C	OF RE	PORTE	R						_			
	202500					AND ADD													
24c. DATE RECEIVED BY MANUFACTURI	ER 24d. REPO	RT SOURCE	LITERATURE																
06-JUL-2025	1-	' 'H ESSIONAL	OTHER: Spont	taneous															
DATE OF THIS REPORT	T 25a. REPO ☑ INITIA		FOLLOWUP:																

ADDITIONAL INFORMATION

7+13. DESCRIBE REACTION(S) continued

The action taken for parecoxib sodium was unknown.

Additional Information: The reporter stated "Hello! I suffer from Ankylosing Spondylitis. I am currently experiencing a flare-up and I haven't been able to find this product of yours near me. Could you please tell me where I can get it?".